# US 11,999,774 B2 · Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,999,774 B2 - Document ID: US11999774B2 - Status: Granted - Kind: B2 - Application number: 17/314,668 - Filed: 2021-05-07 - Published: 2021-09-09 - Granted: 2024-06-04 - Earliest claimed: 2015-07-06 - Assignees: Immatics Biotechnologies GmbH - Applicants: Immatics Biotechnologies GmbH - Inventors: Andrea Mahr; Toni Weinschenk; Colette Song; Oliver Schoor; Jens Fritsche; Harpreet Singh - Web page: https://patentgrep.com/patent/US11999774B2 ## CPC - C07K 14/70539: {MHC-molecules, e.g. HLA-molecules} - A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00) - A61K 39/0011: {Cancer antigens} - A61K 39/001152: {Transcription factors, e.g. SOX or c-MYC} - A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells - A61K 40/42: Cancer antigens - A61P 35/00: Antineoplastic agents - C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE} - C07K 14/635: Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides - C07K 14/7051: {T-cell receptor (TcR)-CD3 complex} - C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules} - C12N 5/0636: {T lymphocytes} - C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]} - C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575) - G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites} - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) - C07K 2319/70: containing domain for protein-protein interaction - C12Q 2600/156: Polymorphic or mutational markers - C12Q 2600/158: Expression markers - C12Q 2600/16: Primer sets for multiplex assays - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. ## Claims ### Claim 1 A peptide consisting of the amino acid sequence HLIAEIHTA (SEQ ID NO: 9) in the form of a pharmaceutically acceptable salt. ### Claim 2 (depends on 1) The peptide of claim 1, wherein said peptide has the ability to bind to an MHC class-I molecule, and wherein said peptide, when bound to said MHC, is capable of being recognized by CD8 T cells. ### Claim 3 (depends on 1) The peptide of claim 1, wherein the pharmaceutically acceptable salt is chloride salt. ### Claim 4 (depends on 1) The peptide of claim 1, wherein the pharmaceutically acceptable salt is acetate salt. ### Claim 5 (depends on 1) A composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier. ### Claim 6 (depends on 5) The composition of claim 5, wherein the peptide is in the form of a chloride salt. ### Claim 7 (depends on 5) The composition of claim 5, wherein the peptide is in the form of an acetate salt. ### Claim 8 (depends on 5) The composition of claim 5, further comprising an adjuvant selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23. ### Claim 9 (depends on 8) The composition of claim 8, wherein the adjuvant is IL-2. ### Claim 10 (depends on 8) The composition of claim 8, wherein the adjuvant is IL-7. ### Claim 11 (depends on 8) The composition of claim 8, wherein the adjuvant is IL-12. ### Claim 12 (depends on 8) The composition of claim 8, wherein the adjuvant is IL-15. ### Claim 13 (depends on 8) The composition of claim 8, wherein the adjuvant is IL-21. ### Claim 14 (depends on 8) The composition of claim 8, wherein the adjuvant is IL-1. ### Claim 15 (depends on 8) The composition of claim 8, wherein the adjuvant is IL-4. ### Claim 16 (depends on 8) The composition of claim 8, wherein the adjuvant is IL-13. ### Claim 17 (depends on 8) The composition of claim 8, wherein the adjuvant is IL-23. ### Claim 18 (depends on 1) The peptide in the form of a pharmaceutically acceptable salt of claim 1, wherein said peptide is produced by solid phase peptide synthesis or produced by a yeast cell or bacterial cell expression system. ### Claim 19 (depends on 1) A composition comprising the peptide of claim 1, wherein the composition is a pharmaceutical composition and comprises water and a buffer. ### Claim 20 A peptide consisting of the amino acid sequence HLIAEIHTA (SEQ ID NO: 9) in the form of a salt.